Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
Not yet recruitingOBSERVATIONAL
Enrollment
460
Participants
Timeline
Start Date
November 1, 2024
Primary Completion Date
November 1, 2027
Study Completion Date
November 1, 2029
Conditions
Mycosis Fungoides/Sezary SyndromeCutaneous T Cell Lymphoma
Interventions
OTHER
Follow-up
Clinical evaluation Blood sample Skin biopsy
All Listed Sponsors
lead
Assistance Publique - Hôpitaux de Paris
OTHER
NCT06651203 - Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study | Biotech Hunter | Biotech Hunter